Aim. To evaluate the efficacy and safety of mosunetuzumab monotherapy in real clinical practice. Materials and methods. The evaluation of the study results included clinical data from 17 patients with follicular lymphoma (7 women and 10 men) who received mosunetuzumab monotherapy in 4 centers of the Russian Federation from November 9, 2021 to April 3, 2025: Botkin Hospital (11 patients), Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation (4 patients), Yaroslavl Regional Clinical Hospital (1 patient), and the National Medical Research Center for Hematology (1 patient). In the evaluated sample, the majority of patients, 15 (88.2 %) people, had a histological variant of the disease: cytological type follicular lymphoma 1–3A. The median age was 43 (22–61) years. All 17 patients had advanced disease stage (III–IV) according to the Ann Arbor classification at the time of diagnosis. The primary endpoint was the frequency of complete response (percentage of patients) over the entire treatment period. Efficacy criteria: overall response rate (complete and partial response) over the entire treatment period, overall and progression-free survival, as well as safety assessment. Results. The overall response rate was 76.4 % (n = 13). Complete response was achieved in 10 (58.8 %) patients. Disease stabilization was observed in 3 (17.6 %) patients, and disease progression was detected in 1 (5.8 %) patient. The median number of mosunetuzumab courses was 6 (2–17). With a median follow-up of 31 (1–43) months in the patient group, the median progression-free survival and overall survival were not achieved. At 42 months, progression-free and overall survival were 67 and 81 %, respectively. Most of the adverse events were mild (I–II). The most common adverse events were hematological complications: anemia, neutropenia, and thrombocytopenia. Grade III–IV adverse events also included anemia (n = 2 (11.7 %)), thrombocytopenia (n = 3 (17.6 %)), and neutropenia (n = 8 (47.0)). Transfusion of blood components was required in 3 (17.6 %) patients. In 1 (5.8 %) case, an episode of febrile neutropenia was noted. Conclusion. The use of mosunetuzumab in real clinical practice has demonstrated high efficacy and a manageable toxicity profile comparable to published data. The results obtained allow us to consider the use of mosunetuzumab as an alternative treatment regimen for patients with relapsed / refractory follicular lymphoma.